Testing reliability of a new PET scan for NSCLC on immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new PET imaging agent to see how consistently it shows immune activity in the body. It is for people with advanced non-small cell lung cancer who are about to start immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You must have non-small cell lung cancer (NSCLC) confirmed by biopsy
- You must be scheduled to receive immunotherapy, alone or with other treatments, for advanced cancer that has spread
- Your cancer must be 'measurable' on scans (not just in one spot)
- You should be able to carry out daily activities with minimal help (ECOG 0, 1, or 2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
This study tests if a new type of PET scan can see changes in your immune system when you receive immunotherapy for non-small cell lung cancer. It may help doctors understand how well your treatment is working.
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
This trial tests a new type of PET scan that uses a special tracer to find lung tumors. The goal is to see if this scan can better detect cancer cells, which may help doctors plan the best treatment for you.
This study tests whether a special PET scan can predict how well a first-line combination of chemotherapy and immunotherapy works in people with advanced non-small cell lung cancer. The goal is to see if the scan can help personalize treatment.
This trial tests a special imaging scan called [18F]-FARAG to see how well it shows the activity of immunotherapy in advanced NSCLC. The goal is to help doctors understand if the treatment is working earlier than standard scans.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.